pharma · Lymphoma · Primary immune thrombocytopenia (ITP)
Hutchison Medi Pharma
Hutchmed Europe B.V.
Hutchison Medi Pharma trial registry — 4 ClinicalTrials.gov studies with program phase, status, and indication context.
Shanghai, CN HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Employees
- 6
- Programs
- 4
- Drugs
- 6
- Patents
- 0
Hutchison Medi Pharma clinical trials
Registry index of 4 ClinicalTrials.gov studies linked to Hutchison Medi Pharma programs — each row shows trial ID, program name, phase, status, and indication.
Hutchison Medi Pharma trial registry — 4 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Hutchison Medi Pharma.
Trial registry
-
CTIS ↗ -
CTIS ↗ - 2024-516369-36-00CTIS ↗
2020-306-GLOB1
- Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)
- 2024-516370-30-00CTIS ↗
A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations
- Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation